DE68929343T2 - Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen - Google Patents
Modifizierte Zellen mit Resistenz gegen RetroviralinfektionenInfo
- Publication number
- DE68929343T2 DE68929343T2 DE68929343T DE68929343T DE68929343T2 DE 68929343 T2 DE68929343 T2 DE 68929343T2 DE 68929343 T DE68929343 T DE 68929343T DE 68929343 T DE68929343 T DE 68929343T DE 68929343 T2 DE68929343 T2 DE 68929343T2
- Authority
- DE
- Germany
- Prior art keywords
- retrovirus
- disclosed
- polynucleotide
- resistance
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010038997 Retroviral infections Diseases 0.000 title abstract 2
- 241001430294 unidentified retrovirus Species 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 150000007523 nucleic acids Chemical group 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 230000010076 replication Effects 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15618888A | 1988-02-16 | 1988-02-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE68929343D1 DE68929343D1 (de) | 2001-12-20 |
DE68929343T2 true DE68929343T2 (de) | 2002-09-12 |
Family
ID=22558494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE68929343T Expired - Fee Related DE68929343T2 (de) | 1988-02-16 | 1989-02-16 | Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen |
Country Status (4)
Country | Link |
---|---|
US (1) | US5324643A (de) |
EP (1) | EP0331939B1 (de) |
AT (1) | ATE208813T1 (de) |
DE (1) | DE68929343T2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658775A (en) * | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
US5278042A (en) * | 1989-02-06 | 1994-01-11 | The United States Of America As Represented By The Department Of Health & Human Services | Method for detecting inhibitors of tat protein |
WO1990011359A1 (en) * | 1989-03-20 | 1990-10-04 | Whitehead Institute For Biomedical Research | Intracellular method of inhibiting hiv in mammalian cells |
JP4041535B2 (ja) * | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ(ユーケー)リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
EP0523140A4 (en) * | 1990-03-21 | 1993-06-16 | Isis Pharmaceuticals, Inc. | Reagents and methods for modulating gene expression through rna mimicry |
US5610050A (en) * | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
US6034233A (en) * | 1990-05-04 | 2000-03-07 | Isis Pharmaceuticals Inc. | 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome |
US5866698A (en) * | 1990-05-04 | 1999-02-02 | Isis Pharmaceuticals, Inc. | Modulation of gene expression through interference with RNA secondary structure |
EP0529008B1 (de) * | 1990-05-04 | 1999-12-15 | Isis Pharmaceuticals, Inc. | Modulation der genexpression durch eingreifen in die rna sekundärstruktur |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
JPH06506599A (ja) * | 1991-04-05 | 1994-07-28 | エディソン アニマル バイオテクノロジー センター,オハイオ ユニバーシティー | パッケージング配列に相補的なアンチセンス核酸によるレトロウイルスの抑制 |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US5693535A (en) * | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
US6451603B1 (en) * | 1992-06-29 | 2002-09-17 | Gene Shears Pty. Limited | Ribozyme nucleic acids and methods of use thereof for controlling viral pathogens |
DE69306969T2 (de) * | 1992-10-05 | 1997-05-07 | Hybridon Inc | Therapeutisches anti-hiv oligonukleotid und arzneimittel |
EP0598935A1 (de) * | 1992-11-24 | 1994-06-01 | Bayer Ag | Expressionsvektoren und deren Verwendung zur Darstellung HIV-resistenter menschlicher Zellen für therapeutische Anwendungen |
US5583035A (en) * | 1992-12-07 | 1996-12-10 | Bayer Aktiengesellschaft | HIV antisense expression vectors |
DE69432409T2 (de) | 1993-04-30 | 2003-12-24 | Wellstat Biologics Corp | Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung |
US6399376B1 (en) | 1993-11-05 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions |
US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
US5902880A (en) * | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
AU2133695A (en) * | 1994-04-06 | 1995-10-30 | Sadna Joshi-Sukhwal | Inhibition of hiv-1 multiplication in mammalian cells |
US5733543A (en) * | 1994-04-29 | 1998-03-31 | Nabel; Gary J. | Introduction of HIV-protective genes into cells by particle-mediated gene transfer |
GB9415129D0 (en) * | 1994-07-27 | 1994-09-14 | Lynxvale Ltd | Oligonucleotides and their use |
US6146886A (en) * | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5990388A (en) * | 1995-06-07 | 1999-11-23 | Research Corporation Technologies, Inc. | Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein |
US6300118B1 (en) | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
US6190861B1 (en) * | 1995-12-14 | 2001-02-20 | The General Hospital Corporation | Molecular sequences of swine retroviruses method of using |
US6699663B1 (en) | 1995-12-14 | 2004-03-02 | The General Hospital Corporation | Molecular sequence of swine retrovirus |
CA2279669A1 (en) * | 1995-12-15 | 1997-06-16 | Enzo Therapeutics, Inc. | Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
US8703480B1 (en) | 1997-03-21 | 2014-04-22 | Enzo Therapeutics, Inc. | Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells |
IL131979A0 (en) * | 1997-03-21 | 2001-03-19 | Enzo Therapeutics Inc | Vectors and viral vectors and packaging cell lines for propagating the same |
ID25877A (id) * | 1997-08-08 | 2000-11-09 | Akzo Nobel Nv | Urutan asam nukleat yang dapat digunakan sebagai primer dan kuar dalam aplifikasi dan deteksi dari seluruh subtipe hiv-1 |
US20060183228A1 (en) * | 1998-03-24 | 2006-08-17 | Enzo Therapeutics, Inc. | Viral vectors with surface or envelope components |
ATE391785T1 (de) | 1999-11-16 | 2008-04-15 | Geneart Ag | Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen |
WO2001051630A1 (en) * | 2000-01-07 | 2001-07-19 | Baylor University | Antisense compositions and methods |
US20070037284A1 (en) * | 2003-06-04 | 2007-02-15 | Enzo Therapeutics, Inc. | Vectors for expressing exogenous gene or exogenous nucleic acid sequences |
EP1742958B1 (de) * | 2004-03-15 | 2017-05-17 | City of Hope | Verfahren und zusammensetzungen für die spezifische hemmung der genexpression durch doppelstrang-rna |
JP6340527B2 (ja) * | 2013-09-20 | 2018-06-13 | 公益財団法人ヒューマンサイエンス振興財団 | Htlv−1プロウイルスを検出するためのキット、htlv−1プロウイルスの検出方法、htlv−1プロウイルスの検出装置及びプログラム |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
ATE201444T1 (de) * | 1985-03-21 | 2001-06-15 | Johnston Stephen Ph D | Vom parasit abgeleiteter widerstand |
PT83682B (en) * | 1985-11-06 | 1988-12-05 | Smithkline Beckman Corp | Process for the expression of an aids virus gene |
WO1987003451A1 (en) * | 1985-12-05 | 1987-06-18 | Fred Hutchinson Cancer Research Center | Anti-sense rna for treatment of retroviral disease states |
IL81568A0 (en) * | 1986-02-14 | 1987-09-16 | Us Commerce | Plasmids which inhibit human t-cell lymphotropic virus type iii replication |
US4935372A (en) * | 1986-05-20 | 1990-06-19 | Dana Farber Cancer Institute | Art nucleotide segments, vectors, cell lines methods of preparation and use |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
EP0291893A1 (de) * | 1987-05-19 | 1988-11-23 | The Du Pont Merck Pharmaceutical Company | Stabile menschliche Zellinien, die ein Indikatorgenprodukt unter virusspezifischen genetischen Kontrollen exprimieren |
-
1989
- 1989-02-16 DE DE68929343T patent/DE68929343T2/de not_active Expired - Fee Related
- 1989-02-16 AT AT89102692T patent/ATE208813T1/de not_active IP Right Cessation
- 1989-02-16 EP EP89102692A patent/EP0331939B1/de not_active Expired - Lifetime
-
1991
- 1991-07-29 US US07/739,718 patent/US5324643A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE208813T1 (de) | 2001-11-15 |
US5324643A (en) | 1994-06-28 |
EP0331939A2 (de) | 1989-09-13 |
DE68929343D1 (de) | 2001-12-20 |
EP0331939A3 (de) | 1991-10-30 |
EP0331939B1 (de) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE208813T1 (de) | Modifizierte zellen mit resistenz gegen retroviralinfektionen | |
DE69434820D1 (de) | Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis | |
CY1106926T1 (el) | Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της | |
DE69434724D1 (de) | Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren | |
DE3650507T2 (de) | Schutz von Pflanzen gegen Virusinfektion | |
DK120091A (da) | Tripelstrenget nukleinsyre og anvendelse heraf | |
ITFI920052A1 (it) | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
ES2165345T3 (es) | Resistencia virica inducible en plantas. | |
ATE93272T1 (de) | Expression von protein c. | |
ES2076143T3 (es) | Plantas resistentes a virus que tienen arn antisentido. | |
BR9811096A (pt) | Sequências, moléculas, vetores e vacinas de dna recombinante para doença do calcivìrus felino e processo para a produção e o uso dos mesmos | |
Raskó et al. | Genes in Medicine: Molecular biology and human genetic disorders | |
ATE166390T1 (de) | Anti-katze immundefiziensvirus (fiv) impfstoffe | |
HUP9904271A2 (hu) | Eljárás vírussal szembeni rezisztencia indukálására növényben | |
Wayne Davies et al. | Nucleotide sequence of the attachment site of coliphage lambda | |
ES2068811T5 (es) | Plantas resistentes a virus que tienen una proteina de cubierta viral. | |
Kolata | Z-DNA Moves Toward" Real Biology" Once considered to be an oddity of no particular significance, this unusual structure is now showing up in DNA segments that control gene expression | |
DE68912228T2 (de) | Verfahren für die Rettung von DNS und für den Nachweis von Mutationen in Markiergenen. | |
DE59209908D1 (de) | Verfahren zur genetischen Manipulation von Myxobakterien | |
Finnegan | I-Factors in Drosophila melanogaster and similar elements in other eukaryotes | |
ATE209440T1 (de) | Resistenzgene gegen fusarsäure | |
DE69025907T2 (de) | Nukleinsäurefragmente und vom HHV6/SIE Virusgenom abgeleitete Diagnosemittel sowie Verfahren zur Diagnose von HHV6 Infektionen | |
Takahashi et al. | Induction of mutation invitro in phage φX174 am3 by N4-aminodeoxycytidine triphosphate | |
DE69533167D1 (de) | Impfstoffe gegen den hepatitis b und c virus | |
Fisher et al. | Evolution of a defective virus from a cellular defense mechanism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |